microcirculationРегионарное кровообращение и микроциркуляцияRegional blood circulation and microcirculation1682-66552712-9756Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1682-6655-2013-12-1-42-47microcirculation-817Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLES (CLINICAL INVESTIGATIONS)31P-магнитно-резонансная спектроскопия у больных артериальной гипертонией с гипертрофией левого желудочка - оценка энергетического метаболизма31P magnetic resonance spectroscopy in hypertensives with left ventricle hypertrophy - assessment of energy metabolismМазаевВ. В.MazaevV. V.dr.vmazaev@gmail.comСтукаловаО. В.StukalovaO. V.noemail@neicon.ruТерновойС. К.TernovoyS. K.tomography.ru@gmail.comЧазоваИ. Е.ChazovaI. E.noemail@neicon.ruРоссийский научно-производственный комплексРоссияRussian Cardiology Research ComplexRussian Federation2013300320131214247Copyright © Мазаев В.В., Стукалова О.В., Терновой С.К., Чазова И.Е., 20132013Мазаев В.В., Стукалова О.В., Терновой С.К., Чазова И.Е.Mazaev V.V., Stukalova O.V., Ternovoy S.K., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.microcirc.ru/jour/article/view/817

Цель - оценить состояние энергетического метаболизма миокарда у больных артериальной гипертонией (АГ) с гипертрофией миокарда левого желудочка (ГЛЖ) по данным 31Р-магнитно-резонансной спектроскопии (31Р МРС) в сравнении со здоровыми лицами. В исследование были включены 46 человек, 30 здоровых добровольцев (группа I), не страдающих сердечнососудистыми заболеваниями (ССЗ), и 16 больных АГ с ГЛЖ (группа II). Всем включенным в исследование лицам была проведена МРТ и МРС сердца на сверхвысокопольном МР-томографе Achieva 3T TX (Philips, Голландия). Для сбора данных использовалась локализация ISIS, адиабатический импульс с итеративным шиммированием. Для оценки энергетического метаболизма миокарда у больных АГ с ГЛЖ использовались два энергетических индекса: ФК/АТФ (отношение концентраций фосфокреатина к аденозинтрифосфату) и НФ/ФК (отношение концентраций неорганического фосфата к фосфокреатину). Величина индекса ФК/АТФ в группе I составила 1,66±0,11, в группе II - 2,08±0,35 (p<0,05). Значение индекса НФ/ФК в группе I составило 8,87±3,14, в группе II - 13,5±3,3 (p<0,05). 31Р МРС может быть использована для определения состояния энергетического метаболизма миокарда у больных АГ с ГЛЖ.

Assess the state of myocardial energy metabolism in patients with arterial hypertension (AH) and left ventricular hypertrophy (LVH) according to 31P magnetic resonance spectroscopy (31P MRS) compared with healthy individuals. The study included 46 people, 30 healthy volunteers (group I) who do not have cardiovascular disease (CVD) and 16 hypertensive patients with LVH (group II). All persons included in the study was performed MRI and MRS of the heart on high field MRI Achieva 3T TX (Philips, The Netherlands). We used the ISIS localization, adiabatic impulse with iterative shimming. To assess myocardial energy metabolism in patients with hypertension and LVH we used two energy indexs: PCr/ATP (the ratio of the concentrations of phosphocreatine to adenosine triphosphate), and Pi/PCr (the ratio of the concentration of inorganic phosphate to phosphocreatine). Index value of PCr/ATP in the group I was 2.08±0.35, in group II - 1.66±0.11, (p <0.05). The value of Pi/PCr in group I was 8.87±3.14, in group II - 13.5±3.3 (p<0.05). 31P MRS can be used to determine the status of myocardial energy metabolism in patients with hypertension and LVH.

магнитно-резонансная спектроскопия31Рметаболизм миокардафосфокреатинаденозинтрифосфатАТФартериальная гипертониягипертрофия миокардаmagnetic resonance spectroscopy31Pmyocardial metabolismphosphocreatineadenosine triphosphateATParterial hypertensionleft ventricle hypertrophyReferencesБеленков Ю. Н. и др. Гипертрофическая кардиомиопатия исторические и современные взгляды на диагностику заболевания // Кардиология и сердечно-сосудистая хирургия. 2008. № 4. С. 4-10.Беленков Ю. Н. и др. Гипертрофическая кардиомиопатия исторические и современные взгляды на диагностику заболевания // Кардиология и сердечно-сосудистая хирургия. 2008. № 4. С. 4-10.Чазова И. Е. Артериальная гипертония: стандарты сегодняшнего дня и нерешенные проблемы // Сердце. 2002. № 1. С. 217-219.Чазова И. Е. Артериальная гипертония: стандарты сегодняшнего дня и нерешенные проблемы // Сердце. 2002. № 1. С. 217-219.Balaban R. S. Regulation of oxidative phosphorylation in the mammalian cell // Am. J. Physiol. 1990. № 258. Р. C377-C389.Balaban R. S. Regulation of oxidative phosphorylation in the mammalian cell // Am. J. Physiol. 1990. № 258. Р. C377-C389.Beer M. Cardiac spectroscopy: techniques, indications and clinical results // Eur. Radiol. 2004. № 14. Р. 1034-1047.Beer M. Cardiac spectroscopy: techniques, indications and clinical results // Eur. Radiol. 2004. № 14. Р. 1034-1047.Bottomley P. A. MR spectroscopy of the human heart: the status and the challenges // Radiology. 1994. № 191. Р. 593-612.Bottomley P. A. MR spectroscopy of the human heart: the status and the challenges // Radiology. 1994. № 191. Р. 593-612.Camici P. et al. Coronary vasodilatation is impaired in both hypertrophied and non-hypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron tomography // J. Am. Coll. Cardiol. 1991. № 17. Р. 879-886.Camici P. et al. Coronary vasodilatation is impaired in both hypertrophied and non-hypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron tomography // J. Am. Coll. Cardiol. 1991. № 17. Р. 879-886.Conway M. A. et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy //Lancet. 1991. № 338. Р. 973-976.Conway M. A. et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy //Lancet. 1991. № 338. Р. 973-976.Conway M. A. et al. Cardiac metabolism during exercise measured by magnetic resonance spectroscopy // Lancet. 1988. № 2. Р. 692.Conway M. A. et al. Cardiac metabolism during exercise measured by magnetic resonance spectroscopy // Lancet. 1988. № 2. Р. 692.de Roos A. et al. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy // J. Magn. Reson. Imaging. 1992. № 2. Р. 711-719.de Roos A. et al. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy // J. Magn. Reson. Imaging. 1992. № 2. Р. 711-719.Devereux R. B. et al. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequense and prognostic implications // J. Hypertens. 1994. Vol. 12. Suppl. P. 117-127.Devereux R. B. et al. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequense and prognostic implications // J. Hypertens. 1994. Vol. 12. Suppl. P. 117-127.Goodwin G. W., Ahmad F., Taegtmeyer H. Preferential oxidation of glycogen in isolated working rat heart // J. Clin. Invest. 1996. № 97. Р. 1409 -1416.Goodwin G. W., Ahmad F., Taegtmeyer H. Preferential oxidation of glycogen in isolated working rat heart // J. Clin. Invest. 1996. № 97. Р. 1409 -1416.Hansch A. R. et al. Jena/DE Noninvasive measurement of cardiac high-energy phosphate metabolites using 31P-spectroscopic chemical shift imaging // ECR. 2009. e-Poster: Р. C-174.Hansch A. R. et al. Jena/DE Noninvasive measurement of cardiac high-energy phosphate metabolites using 31P-spectroscopic chemical shift imaging // ECR. 2009. e-Poster: Р. C-174.Heyne J.-R. et al. Kaiser 31P-MR spectroscopic imaging in hypertensive heart disease // Eur. Radiol. 2006. № 16. Р. 1796-1802.Heyne J.-R. et al. Kaiser 31P-MR spectroscopic imaging in hypertensive heart disease // Eur. Radiol. 2006. № 16. Р. 1796-1802.Kannel W. B. Left ventricular hypertrophy as a risk factor // J. Hypertens. 1991. № 9. Suppl. 2. Р. S3-S9.Kannel W. B. Left ventricular hypertrophy as a risk factor // J. Hypertens. 1991. № 9. Suppl. 2. Р. S3-S9.Kostler H. et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy // Magn. Reson. Med. 2006. № 56. Р. 907-911.Kostler H. et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy // Magn. Reson. Med. 2006. № 56. Р. 907-911.Lamb H. J. et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism // Circulation. 1999. № 99. Р. 2261-2267.Lamb H. J. et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism // Circulation. 1999. № 99. Р. 2261-2267.Loffler R. et al. Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans // J. Magn. Reson. 1998. № 134. Р. 287-299.Loffler R. et al. Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans // J. Magn. Reson. 1998. № 134. Р. 287-299.Lortet S. et al. Alteration of cardiac energy state during development of hypertension in rats of the Lyon strain: a 31P-NMR study on the isolated rat heart // Acta Physiol. Scand. 1993. № 149. Р. 311-321.Lortet S. et al. Alteration of cardiac energy state during development of hypertension in rats of the Lyon strain: a 31P-NMR study on the isolated rat heart // Acta Physiol. Scand. 1993. № 149. Р. 311-321.Maron B. J. Hypertrophic cardiomyopathy // Lancet. 1997. Vol. 350. P. 127-133.Maron B. J. Hypertrophic cardiomyopathy // Lancet. 1997. Vol. 350. P. 127-133.Maron B. J., Epstein S. E., Roberts W. C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries // Am. J. Cardiol. 1979. № 43. Р. 1086-1102.Maron B. J., Epstein S. E., Roberts W. C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries // Am. J. Cardiol. 1979. № 43. Р. 1086-1102.Massie B. M. et al. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy // Circulation. 1995. № 91. Р. 1814-1823.Massie B. M. et al. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy // Circulation. 1995. № 91. Р. 1814-1823.Miller D. D., Walsh R. A. In vivo phosphorus-31 NMR spectroscopy of abnormal myocardial high-energy phosphate metabolism during cardiac stress in hypertensive- hypertrophied non-human primates // Int. J. Card. Imaging. 1990-1991. № 6. Р. 57-70.Miller D. D., Walsh R. A. In vivo phosphorus-31 NMR spectroscopy of abnormal myocardial high-energy phosphate metabolism during cardiac stress in hypertensive- hypertrophied non-human primates // Int. J. Card. Imaging. 1990-1991. № 6. Р. 57-70.Neubauer S. et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy // Circulation. 1997. № 96. Р. 2190-2196.Neubauer S. et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy // Circulation. 1997. № 96. Р. 2190-2196.Neubauer S. Cardiac magnetic resonance spectroscopy: potential clinical applications // Herz. 2000. № 25. Р. 452-460.Neubauer S. Cardiac magnetic resonance spectroscopy: potential clinical applications // Herz. 2000. № 25. Р. 452-460.Neubauer S. et al. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy // J. Investig. Med. 1997. № 45. Р. 453-462.Neubauer S. et al. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy // J. Investig. Med. 1997. № 45. Р. 453-462.Neubauer S. The failing heart an engine out of fuel // N. Engl. J. Med. 2007. № 356 (11). Р. 1140-1151.Neubauer S. The failing heart an engine out of fuel // N. Engl. J. Med. 2007. № 356 (11). Р. 1140-1151.Nienaber C. A. Regional myocardial bloodflow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy // Circulation. 1993. № 87. Р. 1580-1590.Nienaber C. A. Regional myocardial bloodflow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy // Circulation. 1993. № 87. Р. 1580-1590.Okada M. et al. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS // Magn. Reson. Med. 1998. № 39, Р. 772-782.Okada M. et al. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS // Magn. Reson. Med. 1998. № 39, Р. 772-782.Osbakken M. et al. Creatine kinase kinetics studied by phosphorus-31 nuclear magnetic resonance in a canine model of chronic hypertension-induced cardiac hypertrophy // J. Am. Coll. Cardiol. 1992. № 19. Р. 223-228.Osbakken M. et al. Creatine kinase kinetics studied by phosphorus-31 nuclear magnetic resonance in a canine model of chronic hypertension-induced cardiac hypertrophy // J. Am. Coll. Cardiol. 1992. № 19. Р. 223-228.Schaefer S. et al. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia // J. Clin. Invest. 1990. № 85. Р. 706-713.Schaefer S. et al. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia // J. Clin. Invest. 1990. № 85. Р. 706-713.Schocke M. F. et al. Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI) // Magn. Reson. Imaging. 2003. № 21. Р. 553-559.Schocke M. F. et al. Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI) // Magn. Reson. Imaging. 2003. № 21. Р. 553-559.Schulman D. S. et al. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with normal left ventricular remodeling and improved diastolic function // Am. J. Cardiol. 1996. № 78. Р. 56-60.Schulman D. S. et al. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with normal left ventricular remodeling and improved diastolic function // Am. J. Cardiol. 1996. № 78. Р. 56-60.Shivu G. N. et al. 31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3 T // Eur. J. Radiol. 2008.Shivu G. N. et al. 31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3 T // Eur. J. Radiol. 2008.Smith V. et al. Rapid ventricular filling in left ventricular hypertrophy, II: pathologic hypertrophy // J. Am. Coll. Cardiol. 1985. № 5. Р. 869-874.Smith V. et al. Rapid ventricular filling in left ventricular hypertrophy, II: pathologic hypertrophy // J. Am. Coll. Cardiol. 1985. № 5. Р. 869-874.Spindler M. et al. Diastolic dysfunction and altered energetics in the aMHC403/1 mouse model of familial hypertrophic cardiomyopathy // J. Clin. Invest. 1998. № 101. Р. 1775-1783.Spindler M. et al. Diastolic dysfunction and altered energetics in the aMHC403/1 mouse model of familial hypertrophic cardiomyopathy // J. Clin. Invest. 1998. № 101. Р. 1775-1783.Zhang J. et al. Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake: a 31P NMR spectroscopic study // Circulation. 1995. № 92. Р. 1274-1283.Zhang J. et al. Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake: a 31P NMR spectroscopic study // Circulation. 1995. № 92. Р. 1274-1283.Zhang J. et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy // J. Clin. Invest. 1993. № 92. Р. 993-1003.Zhang J. et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy // J. Clin. Invest. 1993. № 92. Р. 993-1003.

The authors declare that there are no conflicts of interest present.